Search

Your search keyword '"Yamaguchi, Junya"' showing total 291 results
Start Over Author "Yamaguchi, Junya"
291 results on '"Yamaguchi, Junya"'

16. On-Site Stimulation of Dendritic Cells by Cancer-Derived Extracellular Vesicles on a Core–Shell Nanowire Platform

Author

Zhang, Min, primary, Ono, Miki, additional, Kawaguchi, Shota, additional, Iida, Mikiko, additional, Chattrairat, Kunanon, additional, Zhu, Zetao, additional, Nagashima, Kazuki, additional, Yanagida, Takeshi, additional, Yamaguchi, Junya, additional, Nishikawa, Hiroyoshi, additional, Natsume, Atsushi, additional, Baba, Yoshinobu, additional, and Yasui, Takao, additional

Published
2024
Full Text
View/download PDF

18. Discrepancy between CARTO and Rhythmia maps for defining the left atrial low-voltage areas in atrial fibrillation ablation

Author

Kaseno, Kenichi, Hasegawa, Kanae, Miyazaki, Shinsuke, Mukai, Moe, Aoyama, Daisetsu, Nodera, Minoru, Hirano, Koudai, Otake, Mika, Nomura, Ryouhei, Miyahara, Kousuke, Ishikawa, Rie, Matsui, Akira, Yamaguchi, Junya, Shiomi, Yuichiro, Tama, Naoto, Ikeda, Hiroyuki, Fukuoka, Yoshitomo, Ishida, Kentaro, Uzui, Hiroyasu, and Tada, Hiroshi

Published
2021
Full Text
View/download PDF

21. Latest classification of ependymoma in the molecular era and advances in its treatment: a review

Author

Yamaguchi, Junya, Ohka, Fumiharu, Motomura, Kazuya, Saito, Ryuta, Yamaguchi, Junya, Ohka, Fumiharu, Motomura, Kazuya, and Saito, Ryuta

Abstract

Ependymoma is a rare central nervous system (CNS) tumour occurring in all age groups and is one of the most common paediatric malignant brain tumours. Unlike other malignant brain tumours, ependymomas have few identified point mutations and genetic and epigenetic features. With advances in molecular understanding, the latest 2021 World Health Organization (WHO) classification of CNS tumours divided ependymomas into 10 diagnostic categories based on the histology, molecular information and location; this accurately reflected the prognosis and biology of this tumour. Although maximal surgical resection followed by radiotherapy is considered the standard treatment method, and chemotherapy is considered ineffective, the validation of the role of these treatment modalities continues. Although the rarity and long-term clinical course of ependymoma make designing and conducting prospective clinical trials challenging, knowledge is steadily accumulating and progress is being made. Much of the clinical knowledge obtained from clinical trials to date was based on the previous histology-based WHO classifications, and the addition of new molecular information may lead to more complex treatment strategies. Therefore, this review presents the latest findings on the molecular classification of ependymomas and advances in its treatment.

Published
2024

22. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas

Author

Motomura, Kazuya, Kibe, Yuji, Ohka, Fumiharu, Aoki, Kosuke, Yamaguchi, Junya, Saito, Ryuta, Motomura, Kazuya, Kibe, Yuji, Ohka, Fumiharu, Aoki, Kosuke, Yamaguchi, Junya, and Saito, Ryuta

Abstract

The 2021 World Health Organization (WHO) classification of central nervous system tumors applied molecular criteria and further integrated histological and molecular diagnosis of gliomas. This classification allows for the diagnosis of isocitrate dehydrogenase wild-type (IDHwt) glioblastoma (GBM), and WHO grade 4 with histologically lower-grade gliomas (LrGGs), even in the absence of high-grade histopathologic features, such as necrosis and/or microvascular proliferation. They contain at least one of the following molecular features: epidermal growth factor receptor amplification, chromosome 7 gain/10 loss, or telomerase reverse transcriptase promoter mutation. In the imaging features at the time of histological diagnosis, a gliomatosis cerebri growth pattern was frequently observed in these tumors. Furthermore, this growth pattern was significantly higher in IDHwt GBM, WHO grade 4, with histological grade II gliomas. Although the exact prognosis of IDHwt GBM, WHO grade 4, with histologically LGGs remains unknown, its OS was approximately 1–2 years similar to that of histologically IDHwt GBM, WHO grade 4, despite histopathological features similar to IDHmut LrGGs. These findings reinforce the need for the analysis of molecular features, regardless of presenting similar clinical characteristics and imaging features to IDHmut LrGGs.

Published
2024

31. MODL-15. ESTABLISHMENT OF ORGANOID MODELS OF PATIENT-DERIVED GH-PRODUCING PITUITARY ADENOMA

Author

Maeda, Sachi, primary, Ohka, Fumiharu, additional, Kanamori, Fumiaki, additional, Okumura, Yuka, additional, Takeuchi, Kazuhito, additional, Nagata, Yuichi, additional, Motomura, Kazuya, additional, Yamaguchi, Junya, additional, Kibe, Yuji, additional, Harada, Hideyuki, additional, Shimizu, Hiroki, additional, Takido, Yuhei, additional, and Saito, Ryuta, additional

Published
2023
Full Text
View/download PDF

35. Atrial fibrillation activation patterns predict freedom from arrhythmias after catheter ablation: utility of ExTRa mapping™

Author

Aoyama, Daisetsu, primary, Miyazaki, Shinsuke, additional, Hasegawa, Kanae, additional, Nomura, Ryohei, additional, Kakehashi, Shota, additional, Mukai, Moe, additional, Miyoshi, Machiko, additional, Yamaguchi, Junya, additional, Sato, Yusuke, additional, Shiomi, Yuichiro, additional, Ikeda, Hiroyuki, additional, Ishida, Kentaro, additional, Uzui, Hiroyasu, additional, and Tada, Hiroshi, additional

Published
2023
Full Text
View/download PDF

36. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant

Author

Maeda, Sachi, Ohka, Fumiharu, Okuno, Yusuke, Aoki, Kosuke, Motomura, Kazuya, Takeuchi, Kazuhito, Kusakari, Hironao, Yanagisawa, Nobuyuki, Sato, Shinya, Yamaguchi, Junya, Tanahashi, Kuniaki, Hirano, Masaki, Kato, Akira, Shimizu, Hiroyuki, Kitano, Yotaro, Yamazaki, Shintaro, Yamashita, Shinji, Takeshima, Hideo, Shinjo, Keiko, Kondo, Yutaka, Wakabayashi, Toshihiko, and Natsume, Atsushi

Published
2020
Full Text
View/download PDF

37. Predictive factors of post‐operative apathy in patients with diffuse frontal gliomas undergoing awake brain mapping.

Author

Motomura, Kazuya, Kawamura, Ai, Ohka, Fumiharu, Aoki, Kosuke, Nishikawa, Tomohide, Yamaguchi, Junya, Kibe, Yuji, Shimizu, Hiroki, Maeda, Sachi, and Saito, Ryuta

Subjects
BRAIN mapping, GLIOMAS, APATHY, CINGULATE cortex, FRONTAL lobe, BODY surface mapping
Abstract

Patients with diffuse frontal gliomas often present with post‐operative apathy after tumour removal. However, the association between apathy and tumour removal of gliomas from the frontal lobe remains unknown. This study aimed to investigate the factors influencing post‐operative apathy after tumour removal in patients with diffuse frontal gliomas. We compared the demographics and clinical characteristics of patients with and without post‐operative apathy in a cohort of 54 patients who underwent awake brain mapping for frontal gliomas. The frequency of clinical parameters such as left‐sided involvement, high‐grade tumour types (WHO grades III, IV), main tumour location in the anterior cingulate gyrus (ACC) and/or dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC) was significantly greater in the apathetic group compared to the non‐apathetic group. The apathetic group scored significantly lower on neuropsychological assessments such as the Letter Fluency Test among the Word Fluency Tests than the non‐pathetic group (p =.000). Moreover, the scores of Parts 3, and 3–1 of the Stroop test were significantly lower in the apathetic group than those in the non‐apathetic group (p =.023,.027, respectively). Multivariate model analysis revealed that the appearance of post‐operative apathy was significantly related to side of the of lesion [left vs. right, hazard ratio (HR) = 8.00, 95% confidence interval (CI) = 1.36–46.96, p =.021], location of the main tumour in the frontal lobe (ACC/DLPFC/OFC vs. others, HR = 7.99, 95% CI = 2.16–29.59, p =.002), and the Letter Fluency Test (HR =.37, 95% CI =.15–.90, p =.028). Post‐operative apathy is significantly associated with ACC and/or DLPFC and OFC in the left hemisphere of diffuse frontal gliomas. Apathy in frontal gliomas is correlated with a decline in the Letter Fluency Test scores. Therefore, this instrument is a potential predictor of post‐operative apathy in patients with diffuse frontal gliomas undergoing awake brain mapping. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Glutamate Spillover Dynamically Strengthens Gabaergic Synaptic Inhibition of the Hypothalamic Paraventricular Nucleus.

Author

Yamaguchi, Junya, Andrade, Mary Ann, Truong, Tamara T., and Toney, Glenn M.

Subjects
*PARAVENTRICULAR nucleus, *GLUTAMATE decarboxylase, *EXCITATORY amino acids, *GLUTAMATE receptors, *GABA
Abstract

The hypothalamic paraventricular nucleus (PVN) is strongly inhibited by γ-aminobutyric acid (GABA) from the surrounding perinuclear zone (PNZ). Because glutamate mediates fast excitatory transmission and is substrate for GABA synthesis, we tested its capacity to dynamically strengthen GABA inhibition. In PVN slices from male mice, bath glutamate applied during ionotropic glutamate receptor blockade increased PNZ-evoked inhibitory postsynaptic currents (eIPSCs) without affecting GABA-A receptor agonist currents or single-channel conductance, implicating a presynaptic mechanism(s). Consistent with this interpretation, bath glutamate failed to strengthen IPSCs during pharmacological saturation of GABA-A receptors. Presynaptic analyses revealed that glutamate did not affect paired-pulse ratio, peak eIPSC variability, GABA vesicle recycling speed, or readily releasable pool (RRP) size. Notably, glutamate–GABA strengthening (GGS) was unaffected by metabotropic glutamate receptor blockade and graded external Ca2+ when normalized to baseline amplitude. GGS was prevented by pan- but not glial-specific inhibition of glutamate uptake and by inhibition of glutamic acid decarboxylase (GAD), indicating reliance on glutamate uptake by neuronal excitatory amino acid transporter 3 (EAAT3) and enzymatic conversion of glutamate to GABA. EAAT3 immunoreactivity was strongly localized to presumptive PVN GABA terminals. High bath K+ also induced GGS, which was prevented by glutamate vesicle depletion, indicating that synaptic glutamate release strengthens PVN GABA inhibition. GGS suppressed PVN cell firing, indicating its functional significance. In sum, PVN GGS buffers neuronal excitation by apparent “over-filling” of vesicles with GABA synthesized from synaptically released glutamate. We posit that GGS protects against sustained PVN excitation and excitotoxicity while potentially aiding stress adaptation and habituation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Supplementary Figures SF1-SF8 from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

Author

Aoki, Kosuke, primary, Suzuki, Hiromichi, primary, Yamamoto, Takashi, primary, Yamamoto, Kimiyo N., primary, Maeda, Sachi, primary, Okuno, Yusuke, primary, Ranjit, Melissa, primary, Motomura, Kazuya, primary, Ohka, Fumiharu, primary, Tanahashi, Kuniaki, primary, Hirano, Masaki, primary, Nishikawa, Tomohide, primary, Shimizu, Hiroyuki, primary, Kitano, Yotaro, primary, Yamaguchi, Junya, primary, Yamazaki, Shintaro, primary, Nakamura, Hideo, primary, Takahashi, Masamichi, primary, Narita, Yoshitaka, primary, Nakada, Mitsutoshi, primary, Deguchi, Shoichi, primary, Mizoguchi, Masahiro, primary, Momii, Yasutomo, primary, Muragaki, Yoshihiro, primary, Abe, Tatsuya, primary, Akimoto, Jiro, primary, Wakabayashi, Toshihiko, primary, Saito, Ryuta, primary, Ogawa, Seishi, primary, Haeno, Hiroshi, primary, and Natsume, Atsushi, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

Author

Aoki, Kosuke, primary, Suzuki, Hiromichi, primary, Yamamoto, Takashi, primary, Yamamoto, Kimiyo N., primary, Maeda, Sachi, primary, Okuno, Yusuke, primary, Ranjit, Melissa, primary, Motomura, Kazuya, primary, Ohka, Fumiharu, primary, Tanahashi, Kuniaki, primary, Hirano, Masaki, primary, Nishikawa, Tomohide, primary, Shimizu, Hiroyuki, primary, Kitano, Yotaro, primary, Yamaguchi, Junya, primary, Yamazaki, Shintaro, primary, Nakamura, Hideo, primary, Takahashi, Masamichi, primary, Narita, Yoshitaka, primary, Nakada, Mitsutoshi, primary, Deguchi, Shoichi, primary, Mizoguchi, Masahiro, primary, Momii, Yasutomo, primary, Muragaki, Yoshihiro, primary, Abe, Tatsuya, primary, Akimoto, Jiro, primary, Wakabayashi, Toshihiko, primary, Saito, Ryuta, primary, Ogawa, Seishi, primary, Haeno, Hiroshi, primary, and Natsume, Atsushi, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Material and Methods from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

Author

Aoki, Kosuke, primary, Suzuki, Hiromichi, primary, Yamamoto, Takashi, primary, Yamamoto, Kimiyo N., primary, Maeda, Sachi, primary, Okuno, Yusuke, primary, Ranjit, Melissa, primary, Motomura, Kazuya, primary, Ohka, Fumiharu, primary, Tanahashi, Kuniaki, primary, Hirano, Masaki, primary, Nishikawa, Tomohide, primary, Shimizu, Hiroyuki, primary, Kitano, Yotaro, primary, Yamaguchi, Junya, primary, Yamazaki, Shintaro, primary, Nakamura, Hideo, primary, Takahashi, Masamichi, primary, Narita, Yoshitaka, primary, Nakada, Mitsutoshi, primary, Deguchi, Shoichi, primary, Mizoguchi, Masahiro, primary, Momii, Yasutomo, primary, Muragaki, Yoshihiro, primary, Abe, Tatsuya, primary, Akimoto, Jiro, primary, Wakabayashi, Toshihiko, primary, Saito, Ryuta, primary, Ogawa, Seishi, primary, Haeno, Hiroshi, primary, and Natsume, Atsushi, primary

Published
2023
Full Text
View/download PDF

43. Data from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

Author

Aoki, Kosuke, primary, Suzuki, Hiromichi, primary, Yamamoto, Takashi, primary, Yamamoto, Kimiyo N., primary, Maeda, Sachi, primary, Okuno, Yusuke, primary, Ranjit, Melissa, primary, Motomura, Kazuya, primary, Ohka, Fumiharu, primary, Tanahashi, Kuniaki, primary, Hirano, Masaki, primary, Nishikawa, Tomohide, primary, Shimizu, Hiroyuki, primary, Kitano, Yotaro, primary, Yamaguchi, Junya, primary, Yamazaki, Shintaro, primary, Nakamura, Hideo, primary, Takahashi, Masamichi, primary, Narita, Yoshitaka, primary, Nakada, Mitsutoshi, primary, Deguchi, Shoichi, primary, Mizoguchi, Masahiro, primary, Momii, Yasutomo, primary, Muragaki, Yoshihiro, primary, Abe, Tatsuya, primary, Akimoto, Jiro, primary, Wakabayashi, Toshihiko, primary, Saito, Ryuta, primary, Ogawa, Seishi, primary, Haeno, Hiroshi, primary, and Natsume, Atsushi, primary

Published
2023
Full Text
View/download PDF

44. Efficacy and safety of bevacizumab, irinotecan, and temozolomide combination for relapsed or refractory pediatric central nervous system embryonal tumor: a single-institution study

Author

Shiba, Yoshiki, primary, Motomura, Kazuya, additional, Taniguchi, Rieko, additional, Kurimoto, Michihiro, additional, Mizutani, Kosuke, additional, Ohka, Fumiharu, additional, Aoki, Kosuke, additional, Ito, Eiji, additional, Nishikawa, Tomohide, additional, Yamaguchi, Junya, additional, Kibe, Yuji, additional, Shimizu, Hiroki, additional, Maeda, Sachi, additional, Nakashima, Takuma, additional, Suzuki, Hiromichi, additional, Muramatsu, Hideki, additional, Takahashi, Yoshiyuki, additional, and Saito, Ryuta, additional

Published
2023
Full Text
View/download PDF

45. Rapid detection of theMYD88 L265Pmutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma

Author

Yamaguchi, Junya, primary, Ohka, Fumiharu, additional, Kitano, Yotaro, additional, Maeda, Sachi, additional, Motomura, Kazuya, additional, Aoki, Kosuke, additional, Takeuchi, Kazuhito, additional, Nagata, Yuichi, additional, Hattori, Hikaru, additional, Tsujiuchi, Takashi, additional, Motomura, Ayako, additional, Nishikawa, Tomohide, additional, Kibe, Yuji, additional, Shinjo, Keiko, additional, Kondo, Yutaka, additional, and Saito, Ryuta, additional

Published
2023
Full Text
View/download PDF

48. Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review

Author

YAMAGUCHI, Junya, MOTOMURA, Kazuya, OHKA, Fumiharu, AOKI, Kosuke, TANAHASHI, Kuniaki, HIRANO, Masaki, CHALISE, Lushun, NISHIKAWA, Tomohide, SHIMIZU, Hiroyuki, NATSUME, Atsushi, WAKABAYASHI, Toshihiko, and SAITO, Ryuta

Subjects
awake brain mapping, long-term survivor, IDH-wildtype glioblastoma, Case Report, supratotal resection
Abstract

Glioblastoma multiforme (GBM) is an aggressive cancer type, with fewer than 3–5% of patients surviving for more than 3 years. We describe a 48-year-old right-handed man who presented with generalized seizure attacks. Magnetic resonance imaging (MRI) revealed a heterogeneous gadolinium-enhancing lesion in the left inferior parietal lobule. The patient underwent awake surgery, and tumor resection included abnormalities on T2-weighted MRI, with subcortical mapping used to identify the deep functional boundaries. After supratotal resection, the tumor was diagnosed as GBM without isocitrate dehydrogenase (IDH) 1 and 2 mutations. At a follow-up evaluation, 9 years and 2 months after the surgery, the patient appeared healthy, and no relapse or recurrence was observed. We present the case of a long-term survivor of IDH-wildtype GBM. This case suggests that supratotal resection with intraoperative awake brain mapping can improve survival without impairing the patient’s neurological functions.

Published
2021

49. CD79BY196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

Author

Yamaguchi, Junya, primary, Ohka, Fumiharu, additional, Lushun, Chalise, additional, Motomura, Kazuya, additional, Aoki, Kosuke, additional, Takeuchi, Kazuhito, additional, Nagata, Yuichi, additional, Ito, Satoshi, additional, Mizutani, Nobuhiko, additional, Ohno, Masasuke, additional, Suzaki, Noriyuki, additional, Takasu, Syuntaro, additional, Seki, Yukio, additional, Kano, Takahisa, additional, Wakabayashi, Kenichi, additional, Oyama, Hirofumi, additional, Kurahashi, Shingo, additional, Tanahashi, Kuniaki, additional, Hirano, Masaki, additional, Shimizu, Hiroyuki, additional, Kitano, Yotaro, additional, Maeda, Sachi, additional, Yamazaki, Shintaro, additional, Wakabayashi, Toshihiko, additional, Kondo, Yutaka, additional, Natsume, Atsushi, additional, and Saito, Ryuta, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results